WO2004017950A3 - Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents - Google Patents

Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents Download PDF

Info

Publication number
WO2004017950A3
WO2004017950A3 PCT/GB2003/003676 GB0303676W WO2004017950A3 WO 2004017950 A3 WO2004017950 A3 WO 2004017950A3 GB 0303676 W GB0303676 W GB 0303676W WO 2004017950 A3 WO2004017950 A3 WO 2004017950A3
Authority
WO
WIPO (PCT)
Prior art keywords
biphosphate
inhibitors
phosphadidylinositol
viral agents
viral
Prior art date
Application number
PCT/GB2003/003676
Other languages
French (fr)
Other versions
WO2004017950A2 (en
Inventor
Peter Parker
Michael Waterfield
Original Assignee
Piramed Ltd
Peter Parker
Michael Waterfield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramed Ltd, Peter Parker, Michael Waterfield filed Critical Piramed Ltd
Priority to AU2003255845A priority Critical patent/AU2003255845A1/en
Publication of WO2004017950A2 publication Critical patent/WO2004017950A2/en
Publication of WO2004017950A3 publication Critical patent/WO2004017950A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Phosphatidylinositol 3,5-biphosphate signaling has been found to be critical to the process of viral sorting, traffiking and viral budding from mammalian cells. Inhibitors of the phosphatidylinositol 3,5-biphosphate pathway therefore have activity as anti-viral agents.
PCT/GB2003/003676 2002-08-22 2003-08-22 Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents WO2004017950A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003255845A AU2003255845A1 (en) 2002-08-22 2003-08-22 Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40554802P 2002-08-22 2002-08-22
US60/405,548 2002-08-22

Publications (2)

Publication Number Publication Date
WO2004017950A2 WO2004017950A2 (en) 2004-03-04
WO2004017950A3 true WO2004017950A3 (en) 2004-05-13

Family

ID=31946891

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003676 WO2004017950A2 (en) 2002-08-22 2003-08-22 Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents

Country Status (2)

Country Link
AU (1) AU2003255845A1 (en)
WO (1) WO2004017950A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8716480B2 (en) 2009-05-12 2014-05-06 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8748621B2 (en) 2007-09-14 2014-06-10 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8835441B2 (en) 2005-05-20 2014-09-16 Amgen Inc. Heterobicyclic metalloprotease inhibitors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
MXPA05009818A (en) 2003-03-31 2006-03-13 Predix Pharmaceuticals Holding New piperidinylamino-thieno[2,3-d] pyrimidine compounds.
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2007054556A1 (en) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (en) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazine derivatives and their use as signal transduction modulators
PL1966214T3 (en) 2005-12-21 2017-04-28 Janssen Pharmaceutica N.V. Triazolopyridazines as tyrosine kinase modulators
MX2008013583A (en) * 2006-04-26 2008-10-31 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them.
EP2402347A1 (en) 2006-04-26 2012-01-04 F. Hoffmann-La Roche AG Pharmaceutical compounds
US8252792B2 (en) 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
EP2114949A1 (en) 2006-12-07 2009-11-11 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
ES2399774T3 (en) 2007-09-24 2013-04-03 Genentech, Inc. Thiazolopyrimidine compounds PI3K inhibitors and methods of use
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
DK2222675T3 (en) 2007-12-19 2013-11-04 Genentech Inc 5-ANILINOIMIDAZOPYRIDINES AND PROCEDURES FOR THEIR USE
KR20100099185A (en) 2007-12-21 2010-09-10 제넨테크, 인크. Azaindolizines and methods of use
JP5394404B2 (en) 2008-02-06 2014-01-22 ブリストル−マイヤーズ スクイブ カンパニー Substituted imidazopyridazines useful as kinase inhibitors
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
US8394823B2 (en) 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
TWI491610B (en) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 Imidazopyridazinecarbonitriles useful as kinase inhibitors
EP2445877B1 (en) 2008-12-03 2014-07-23 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
SG196815A1 (en) 2009-01-08 2014-02-13 Curis Inc Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
WO2010091150A1 (en) 2009-02-05 2010-08-12 Immunogen, Inc. Novel benzodiazepine derivatives
WO2010105008A2 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
EP2483277B1 (en) 2009-09-28 2015-12-02 F. Hoffmann-La Roche AG Benzoxepin pi3k inhibitor compounds and methods of use
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
JP5641664B2 (en) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ Imidazo [1,2-b] pyridazine derivatives and their use as PDE10 inhibitors
AU2010316780B2 (en) 2009-11-05 2015-07-16 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
AU2010316700A1 (en) 2009-11-06 2012-05-31 Piramal Enterprises Limited Imidazopyridine derivatives
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
CN102558185B (en) * 2010-12-09 2016-02-10 中国科学院上海药物研究所 Pyrido pyrrole triazine compound, Preparation Method And The Use
EP3053600B1 (en) 2011-02-15 2020-01-29 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
AU2012236367B2 (en) 2011-04-01 2014-10-09 Curis, Inc. Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ES2710874T3 (en) 2011-05-04 2019-04-29 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
EP3048106B1 (en) 2011-11-23 2019-11-06 Cancer Research Technology Limited Thienopyrimidine as inhibitors of atypical protein kinase c
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
CN109939236A (en) 2012-06-08 2019-06-28 豪夫迈·罗氏有限公司 Catastrophic selection and the combination of Phosphoinositide-3 kinase inhibitor compound and chemotherapeutics for treating cancer
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
CN104470923B (en) 2012-07-04 2019-03-29 理森制药股份公司 Selective PI3K δ inhibitor
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
JP6423804B2 (en) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド Complex containing cell binding agent and cytotoxic agent
JP6494533B2 (en) 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド Complexes comprising maytansinoids as cell binding agents and cytotoxic agents
ES2700541T3 (en) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, its preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
UA121965C2 (en) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR102502485B1 (en) 2014-01-21 2023-02-21 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
JP6602779B2 (en) 2014-02-13 2019-11-06 インサイト・コーポレイション Cyclopropylamines as LSD1 inhibitors
PE20161573A1 (en) 2014-02-13 2017-01-19 Incyte Corp CYCLOPROPYLAMINE AS AN INHIBITOR OF LSD1
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
ES2909793T3 (en) 2014-04-30 2022-05-10 Univ Columbia Substituted 4-phenylpiperidines, their preparation and use
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TWI687419B (en) 2014-07-10 2020-03-11 美商英塞特公司 Imidazopyridines and imidazopyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10729694B2 (en) 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
WO2016126724A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
AR104068A1 (en) 2015-03-26 2017-06-21 Hoffmann La Roche COMBINATIONS OF A 3-KINASE PHOSFOINOSYTIDE INHIBITOR COMPOSITE AND A CDK4 / 6 INHIBITOR COMPOUND FOR CANCER TREATMENT
MY191796A (en) 2015-04-03 2022-07-15 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
MA42606A (en) 2015-08-12 2018-06-20 Incyte Corp SALTS OF LSD1 INHIBITOR
WO2017184934A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
EP3507305A1 (en) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN109453174B (en) * 2018-11-13 2021-10-22 武汉生物技术研究院 Application of effective inhibitor of type III phosphatidylinositol phosphokinase in preparation of medicine for treating or preventing influenza virus infection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
WO2001009375A2 (en) * 1999-07-30 2001-02-08 University College London Inducible screen for drug discovery
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
WO2003002528A2 (en) * 2001-06-29 2003-01-09 Subsidiary No. 3 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2003060067A2 (en) * 2001-11-09 2003-07-24 Proteologics, Inc. P85-alpha nucleic acids, polypeptides and related methods

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
WO2001009375A2 (en) * 1999-07-30 2001-02-08 University College London Inducible screen for drug discovery
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001064674A1 (en) * 2000-03-01 2001-09-07 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2001083481A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
EP1277738A1 (en) * 2000-04-27 2003-01-22 Yamanouchi Pharmaceutical Co. Ltd. Condensed heteroaryl derivatives
EP1277754A1 (en) * 2000-04-27 2003-01-22 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives
WO2003002528A2 (en) * 2001-06-29 2003-01-09 Subsidiary No. 3 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2003060067A2 (en) * 2001-11-09 2003-07-24 Proteologics, Inc. P85-alpha nucleic acids, polypeptides and related methods

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GUEIFFIER A ET AL: "SYNTHESIS OF IMIDAZO1,2-APYRIDINES AS ANTIVIRAL AGENTS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 25, 1998, pages 5108 - 5112, XP001038335, ISSN: 0022-2623 *
IKONOMOV OGNIAN C ET AL: "Mammalian cell morphology and endocytic membrane homeostasis require enzymatically active phosphoinositide 5-kinase PIKfyve", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 28, 13 July 2001 (2001-07-13), pages 26141 - 26147, XP002263020, ISSN: 0021-9258, Retrieved from the Internet <URL:http://www.jbc.org> [retrieved on 20031127] *
JOHNSON ROBERT A ET AL: "Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: Inhibition of PI3-K activity inhibits viral replication and virus-induced signaling", JOURNAL OF VIROLOGY, vol. 75, no. 13, July 2001 (2001-07-01), pages 6022 - 6032, XP002263019, ISSN: 0022-538X, Retrieved from the Internet <URL:http://jvi.asm.org> [retrieved on 20031125] *
LINNEMANN T ET AL: "Interaction between Nef and Phosphatidylinositol-3-Kinase Leads to Activation of p21-Activated Kinase and Increased Production of HIV", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 294, no. 2, 15 March 2002 (2002-03-15), pages 246 - 255, XP004467122, ISSN: 0042-6822 *
MAVEL SYLVIE ET AL: "Influence of 2-substituent on the activity of imidazo(1,2-a)pyridine derivatives against human cytomegalovirus", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 10, no. 4, April 2002 (2002-04-01), pages 941 - 946, XP002269344, ISSN: 0968-0896, Retrieved from the Internet <URL:www.sciencedirect.com> [retrieved on 20040206] *
MERINO I ET AL: "SYNTHESIS AND ANTI-HIV-1 ACTIVITIES OF NEW PYRIMIDO5,4-BINDOLES", FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 54, 1999, pages 255 - 264, XP002944143, ISSN: 0014-827X *
WURMSER ANDREW E ET AL: "Phosphoinositide 3-kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 14, 2 April 1999 (1999-04-02), pages 9129 - 9132, XP002263021, ISSN: 0021-9258, Retrieved from the Internet <URL:http://www.jbc.org> [retrieved on 20031127] *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835441B2 (en) 2005-05-20 2014-09-16 Amgen Inc. Heterobicyclic metalloprotease inhibitors
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8748621B2 (en) 2007-09-14 2014-06-10 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8716480B2 (en) 2009-05-12 2014-05-06 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Also Published As

Publication number Publication date
AU2003255845A1 (en) 2004-03-11
WO2004017950A2 (en) 2004-03-04
AU2003255845A8 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004017950A3 (en) Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
NZ712789A (en) Placental stem cell populations
MX2009009225A (en) Definitive endoderm.
WO2005116073A3 (en) Pdx1 expressing endoderm
EP2317316A3 (en) Methods for identifying agent and conditions that modulate neurogenesis
NO20001583D0 (en) Stimulation of hematopoietic cells in vitro
EP2266396A3 (en) Modulation of stem cells using zinc finger proteins
IL159475A0 (en) Spherical protein particles, compositions containing the same and methods for the production thereof
RS52891B (en) Gastroresistant pharmaceutical formulations containing rifaximin
WO2004015077A3 (en) Compositions and methods for neural differentiation of embryonic stem cells
WO2007086967A3 (en) Small particle compositions and associated methods
MXPA05012319A (en) Delivery of compounds with rehydrated blood cells.
USD527893S1 (en) Ankle cell phone holder
EP1319402A4 (en) Ige production inhibitors
WO2000015764A3 (en) Propagation and/or derivation of embryonic stem cells
AU2003209297A1 (en) Methods and compositions for preserving the viability of photoreceptor cells
GB2409645A (en) Flower essence-containing medicaments
AU2003287521A1 (en) Pluripotent cells from monocytes, and methods of making and using pluripotent cells
WO2003106625A3 (en) Hammerhead ribozymes
EP1356076A4 (en) Methods and compositions for extracting proteins from cells
DE60107718T8 (en) PRESERVATION OF CELLS
AU2003288621A1 (en) Rna bioassay
WO2004090121A3 (en) Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
SI1244643T1 (en) Tryptase inhibitors
SI1244614T1 (en) Tryptase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP